Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Centers for Disease Control and Prevention

    - PMLiVE

    Sanofi to expand respiratory vaccines pipeline with $1.6bn Vicebio acquisition

    The deal includes an early-stage combination vaccine candidate for RSV and hMPV

    - PMLiVE

    Moderna shares positive phase 3 results for mRNA flu vaccine candidate

    More than 600,000 people in the US were hospitalised due to flu-related illness last year

    - PMLiVE

    Moderna’s RSV vaccine mRESVIA granted FDA approval to protect younger adults

    The vaccine is already approved in the US for use in adults aged 60 years and older

    - PMLiVE

    Merck’s RSV monoclonal antibody Enflonsia approved by FDA to protect infants

    Enflonsia is now the first RSV preventive for infants that can be given at the same dose regardless of weight

    - PMLiVE

    Pfizer’s RSV vaccine receives EC approval for individuals aged 18 to 59 years

    Abrysvo is now the first RSV vaccine in the EU for non-pregnant adults in this age group

    - PMLiVE

    Moderna’s RSV vaccine mRESVIA granted MHRA approval to protect older adults

    RSV is responsible for 14,000 hospitalisations per year in UK adults aged 65 years and older

    - PMLiVE

    Seven strategic steps to enhance patient recruitment & retention in your influenza studies

    The development of all treatments, including vaccines, is dependent on people taking part in clinical trials but this can be challenging for influenza studies, especially given the typically short patient...

    Innovative Trials

    - PMLiVE

    Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study

    The serious adverse event reported was found to be unrelated to the vaccine

    - PMLiVE

    UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance

    The new analysis found that RSV infections lead to 640,000 antibiotic prescriptions every year

    - PMLiVE

    GSK’s RSV vaccine Arexvy shown to protect older adults across three seasons

    The respiratory virus is estimated to impact 64 million people globally every year

    - PMLiVE

    Moderna’s JN.1-adapted COVID-19 vaccine approved by MHRA for adults and children

    The JCVI has already advised the UK government on eligible groups for this year’s autumn vaccination programme

    - PMLiVE

    Novavax’s JN.1-adapted COVID-19 vaccine granted FDA emergency use authorisation

    JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links